Site icon Impactiviti

Today’s Top Three in Pharma 032609

Psychiatrists – no more $$, thanksAmid the flak surrounding several prominent psychiatrists (see here and here) and their ties to the drug industry, the American Psychiatric Association has decided to drop all industry-sponsored meals and educational sessions from its annual conferences, the group announced today.

Novo may dodge Takeda‘s fate with new diabetes drug approval by FDA“Given the Takeda experience, people are more cautious,” said Jack Scannell, a Sanford C. Bernstein & Co. analyst in London. “We’ve gone from a world where people thought liraglutide would sail through the advisory committee to a world where people are aware it’s not a dead certainty.” Scannell expects the drug to “scrape through” the advisory panel meeting, win FDA approval and generate a peak of $1 billion in U.S. revenue by 2013. Its sales potential is limited by gastrointestinal side effects that may lead some patients to opt against it, he said in a telephone interview.

The Pfizer/Ligand osteo drug – Yes in the EU; We’ll see in the United States.


Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Exit mobile version